NASDAQ: BBOT
Bridgebio Oncology Therapeutics Inc Stock Ownership - Who owns Bridgebio Oncology Therapeutics?

Insider buying vs selling

Have Bridgebio Oncology Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Bihua ChenDirector2025-08-11760,496$10.72
$8.15MBuy
Bihua ChenDirector2025-08-11639,110$10.72
$6.85MBuy
Bihua ChenDirector2025-08-115,598,425$10.72
$60.00MBuy

1 of 1

BBOT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BBOT insiders and whales buy or sell their stock.

BBOT Shareholders

What type of owners hold Bridgebio Oncology Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bihua Chen23.48%18,782,194$216.00MInsider
Cormorant Asset Management LP22.35%17,878,594$205.60MInstitution
Bridgebio Pharma LLC18.24%14,589,846$167.78MInsider
Deerfield Management Company LP6.11%4,885,446$56.18MInstitution
Omega Fund Management LLC4.11%3,289,661$37.83MInstitution
Wellington Management Group LLP3.70%2,961,263$34.05MInstitution
Ecor1 Capital LLC3.53%2,823,126$32.47MInstitution
Alphabet Inc3.53%2,823,126$32.47MInstitution
Enavate Sciences GP LLC3.28%2,626,946$30.21MInstitution
Citadel Advisors LLC3.17%2,538,141$29.19MInstitution

1 of 3

BBOT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BBOT62.58%37.42%Net Buying
CTMX81.09%12.77%Net SellingNet Selling
XNCR72.06%27.94%Net SellingNet Buying
BCAX70.36%29.64%Net SellingNet Buying
IOVA16.41%83.59%Net SellingNet Selling

Bridgebio Oncology Therapeutics Stock Ownership FAQ

Who owns Bridgebio Oncology Therapeutics?

Bridgebio Oncology Therapeutics (NASDAQ: BBOT) is owned by 71.03% institutional shareholders, 42.47% Bridgebio Oncology Therapeutics insiders, and 0.00% retail investors. Bihua Chen is the largest individual Bridgebio Oncology Therapeutics shareholder, owning 18.78M shares representing 23.48% of the company. Bihua Chen's Bridgebio Oncology Therapeutics shares are currently valued at $214.40M.

If you're new to stock investing, here's how to buy Bridgebio Oncology Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.